May 19, 2016 : Latest SGLT-2 Inhibitors News

LATEST NEWS

AACE/ACE Position Statement On SGLT-2 Inhibitors and DKA Risk

DISASTERS AVERTED — Near Miss Case Studies

Make the Goal Personal to Motivate

EXCLUSIVE INTERVIEW: Candid Interviews with Top Practitioners

Transcript: Dr. Aaron Vinik Discusses the Shift in Diabetes Care

Sometimes we are so interested in the process that we forget to look for the outcome with our patients. This means we take our diabetes patients and start low and go slow. This kind of treatment regimen may be following the “guidelines” but oftentimes getting to the goal we want for our patients takes too long, and by the time we get close to where we want to be the complications of diabetes force us to treat more than just a high A1C. One of those complications is heart disease, and any therapy that works to prevent that complication is worth getting started on quickly. One of the best ways is to get our patients on an SGLT-2 inhibitor. They are safe, effective for glucose lowering, can help patients lose weight and, depending on which one you choose, there is great evidence that they can reduce heart risks. To learn more about this class of drugs and maybe change your “guidelines,” check out the month’s exclusive from Dr. Aaron Vinik.

Your partner in diabetes care,
Dave Joffe
Editor-in-chief

A year after the FDA warning, a strong response to the question: are SGLT-2 inhibitors safe?

Male, 66 years of age, type 2 diabetes, class III obesity, peripheral neuropathy, multiple toe amputations, hypertension, hyperlipidemia and, most importantly, a 2-year-old granddaughter. Patient taking 100 units long-acting insulin, sulfonylurea, metformin, beta blocker, and statin. Checks glucose once in a while; in the 200 to 270 range when checks. A1C 9.3%.

In part 1 of this exclusive interview, DIC publisher Steve Freed talks with Dr. Aaron Vinik about the shift away from rigorous glycemic control in favor of greater focus on the impact of diabetes treatment on the heart.